DataSheet_1_Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.pdf
We determined first- and second-line regimens, including hematopoietic stem cell transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged ≥20 yr (n = 1,888), registered at the Belgian Cancer Registry (2013–2015). Treatments were inferred from reimbursed drugs, and procedures registered in national health insurance databases. This real-world population-based study allows to assess patients usually excluded from clinical trials such as those with comorbidities, other malignancies (12%), and advanced age (28% are ≥80 yr old). Our data show that the majority of older patients a... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Dataset |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Cancer / Cancer Cell Biology / Cancer Diagnosis / Cancer Genetics / Cancer Therapy (excl. Chemotherapy and Radiation Therapy) / Chemotherapy / Haematological Tumours / Molecular Targets / Radiation Therapy / Solid Tumours / Oncology and Carcinogenesis not elsewhere classified / DLBCL - diffuse large B cell lymphoma / population-based cancer registry / health insurance database / first- and second-line therapy / R-CHOP / hematopoietic stem cell transplantation / comorbidities / real-world studies (RWS) |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-26528461 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3389/fonc.2022.824704.s001 |